A Phase 3 interventional study of Tadalafil and Placebo in Hypertension, Pulmonary, sponsored by Eli Lilly and Company. Completed at 43 sites in 14 countries. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2021-11-05.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing tadalafil in Hypertension, Pulmonary — 3 open to participants now, 3 under way, 2 of them phase 3. Tadalafil · Hypertension, Pulmonary.
Among the 18 studies testing tadalafil in Hypertension, Pulmonary, this one is the 10th largest by enrollment, is the only one that started in 2014, is one of 8 in phase 3, and was the 10th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →3 of the 18 studies testing tadalafil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 35–89
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–85
Actelion · Sites in Belarus, Belgium, Bulgaria and 10 more countries
Ages 2+
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 6 Months to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is close to the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 40 across the 18 interventional studies. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 18 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 3 studies filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
2 of the studies testing tadalafil in Hypertension, Pulmonary that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
| NCT05844462Phase 3Assistance Publique - Hôpitaux de ParisTadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies testing tadalafil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and efficacy of tadalafil in pediatric participants with pulmonary arterial hypertension. Participants will receive study treatment for 6 months in the double-blind period (Period 1), and then will be eligible to enroll into an open-label 2 year extension period (Period 2) during which participants will receive tadalafil.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Currently have a diagnosis of PAH that is either:
Exclusion Criteria:
History of left-sided heart disease, including any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: 20 mg or 40 mg administered orally by tablets once a day. Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day. Final tadalafil doses for Period 1 (6-month double-blind) were assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431).Tadalafil doses would range from 5 milligram (mg) to 40 mg depending on body weight cohorts. Heavy weight cohort ≥40 kilogram (kg), Middle weight cohort ≥25 kg to \<40 kg: administered orally by tablets once a day. Light weight cohort \<25 kg: administered orally by suspension once a day. Participants receiving tadalafil in Period 1 continued to receive tadalafil during Period 2 (2-year open-label extension).
Drug: Tadalafil · Drug: ERA as specific PAH treatment
Period 1: Participants received placebo orally by tablets once a day. Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day. Final placebo dose for Period 1 (6-month double-blind) was be assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431) to maintain blinding depending on body weight cohort. Participants receiving placebo in Period 1 Period 2 (2-year open-label extension) would receive tadalafil in Period 2 at the corresponding tadalafil dose in that participant's weight group.
Drug: Placebo · Drug: ERA as specific PAH treatment
Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
Also known as: LY450190, Cialis, Adcirca, IC351
Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).
Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters
6MWD in meters assessed in a subset of participants who are ≥6 to \<18 years of age who are developmentally capable of performing a 6MW test. Change from baseline was derived using mixed model repeated measures (MMRM) with terms for treatment group, visit, baseline 6MWD, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Period 1: Time to Adjudicated Clinical Worsening (CW)
Clinical worsening was defined as any of the following: death,lung or heart transplantation,atrial septostomy or Potts' shunt,hospitalization for Pulmonary Arterial Hypertension(PAH) progression,new onset syncope,initiation of new PAH therapy(including increase in the dose of existing PAH specific concomitant therapy,such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class(except for participants already in Class IV;only for participants unable to perform the 6 minute walk(6MW) test;worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk(6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance(for those participants who are ≥6 years of age). Criteria for CW(from Period 1) were adjudicated by an independent,blinded study-specific Clinical Endpoint Committee(CEC).This adjudication was used for data analysis, and was not used to guide subject treatment.
Time frame: Baseline through Week 24
Period 1: Percentage of Participants Who Experience CW
Clinical worsening was defined as any of the following: death,lung or heart transplantation,atrial septostomy or Potts' shunt,hospitalization for Pulmonary Arterial Hypertension(PAH) progression,new onset syncope, initiation of new PAH therapy(including increase in the dose of existing PAH specific concomitant therapy,such as endothelin receptor agonist or beraprost medication),or increase of 1 or more in World Health Organization(WHO) Functional Class(except for participants already in Class IV; only for participants unable to perform the 6 minute walk(6MW) test;worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk(6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance(for those participants who are ≥6 years of age).Criteria for CW(from Period 1) were adjudicated by an independent,blinded study-specific Clinical Endpoint Committee(CEC).This adjudication was used for data analysis, and was not used to guide subject treatment.
Time frame: Baseline through Week 24
Period 1: Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil at Steady-state
Period 1: Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil at steady-state
Time frame: Week 2, Week 4, Week 16 and Week 24
Period 2: Percentage of Participants Who Experience CW
Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance (for those participants who are ≥6 years of age).
Time frame: Period 2 Baseline through Study Completion (Up to 24 Months)
Period 2: Time to First Occurrence of CW
Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance (for those participants who are ≥6 years of age).
Time frame: Period 2 Baseline through Study Completion (Up to 24 Months)
| Milestone | Placebo | Tadalafil | Placebo/Tadalafil | Tadalafil/Tadalafil |
|---|---|---|---|---|
| Started | 18 | 17 | 0 | 0 |
| Received at least one dose of study drug | 18 | 17 | 0 | 0 |
| Received 20 mg | 0 | 4 | 0 | 0 |
| Received 40 mg | 0 | 13 | 0 | 0 |
| Completed | 15 | 15 | 0 | 0 |
| Not completed | 3 | 2 | 0 | 0 |
| Withdrew: Entry criteria not met | 1 | 0 | 0 | 0 |
| Withdrew: Parent/caregiver decision | 1 | 1 | 0 | 0 |
| Withdrew: Investigator reported clinical worsening | 1 | 1 | 0 | 0 |
| Milestone | Placebo | Tadalafil | Placebo/Tadalafil | Tadalafil/Tadalafil |
|---|---|---|---|---|
| Started | 0 | 0 | 16 | 16 |
| Received 20 mg | 0 | 0 | 3 | 3 |
| Received 40 mg | 0 | 0 | 13 | 13 |
| Completed | 0 | 0 | 13 | 13 |
| Not completed | 0 | 0 | 3 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Parent/caregiver decision | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 1 |
6MWD in meters assessed in a subset of participants who are ≥6 to \<18 years of age who are developmentally capable of performing a 6MW test. Change from baseline was derived using mixed model repeated measures (MMRM) with terms for treatment group, visit, baseline 6MWD, and treatment-by-visit interaction.
| Meters | Placebo | Tadalafil |
|---|---|---|
| Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters | 36.60 ± 20.776 | 60.48 ± 20.410 |
Clinical worsening was defined as any of the following: death,lung or heart transplantation,atrial septostomy or Potts' shunt,hospitalization for Pulmonary Arterial Hypertension(PAH) progression,new onset syncope,initiation of new PAH therapy(including increase in the dose of existing PAH specific concomitant therapy,such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class(except for participants already in Class IV;only for participants unable to perform the 6 minute walk(6MW) test;worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk(6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance(for those participants who are ≥6 years of age). Criteria for CW(from Period 1) were adjudicated by an independent,blinded study-specific Clinical Endpoint Committee(CEC).This adjudication was used for data analysis, and was not used to guide subject treatment.
| Weeks | Placebo | Tadalafil |
|---|---|---|
| Period 1: Time to Adjudicated Clinical Worsening (CW) | NA (NA to NA) | NA (NA to NA) |
Clinical worsening was defined as any of the following: death,lung or heart transplantation,atrial septostomy or Potts' shunt,hospitalization for Pulmonary Arterial Hypertension(PAH) progression,new onset syncope, initiation of new PAH therapy(including increase in the dose of existing PAH specific concomitant therapy,such as endothelin receptor agonist or beraprost medication),or increase of 1 or more in World Health Organization(WHO) Functional Class(except for participants already in Class IV; only for participants unable to perform the 6 minute walk(6MW) test;worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk(6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance(for those participants who are ≥6 years of age).Criteria for CW(from Period 1) were adjudicated by an independent,blinded study-specific Clinical Endpoint Committee(CEC).This adjudication was used for data analysis, and was not used to guide subject treatment.
| percentage of participants | Placebo | Tadalafil |
|---|---|---|
| Period 1: Percentage of Participants Who Experience CW | 0 | 0 |
Period 1: Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil at steady-state
| Liter Per Hour (L/hr) | 20 mg Tadalafil | 40 mg Tadalafil |
|---|---|---|
| With concomitant bosentan | 3.63 ± 38.1 | 4.49 ± 28.2 |
| No bosentan (ERA: Macitentan) | NA ± NA | — |
Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance (for those participants who are ≥6 years of age).
| percentage of participants | Placebo/Tadalafil - Open-Label Treatment | Tadalafil/Tadalafil - Open-Label Treatment |
|---|---|---|
| Period 2: Percentage of Participants Who Experience CW | 12.5 | 18.8 |
Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance (for those participants who are ≥6 years of age).
| Months | Placebo/Tadalafil - Open-Label Treatment | Tadalafil/Tadalafil - Open-Label Treatment |
|---|---|---|
| Period 2: Time to First Occurrence of CW | NA (NA to NA) | NA (NA to NA) |
Collected over Baseline Up To 24 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Double Blind | 0/18 (0%) | 0/18 (0%) | 8/18 (44.4%) |
| Tadalafil - Double Blind | 0/17 (0%) | 0/17 (0%) | 15/17 (88.2%) |
| Placebo/Tadalafil - Open-Label Treatment | 0/16 (0%) | 4/16 (25%) | 11/16 (68.8%) |
| Tadalafil/Tadalafil - Open-Label Treatment | 0/16 (0%) | 1/16 (6.3%) | 12/16 (75%) |
| Event | Placebo - Double Blind | Tadalafil - Double Blind | Placebo/Tadalafil - Open-Label Treatment | Tadalafil/Tadalafil - Open-Label Treatment |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/18 | 0/17 | 1/16 | 0/16 |
| Acute right ventricular failureCardiac disorders | 0/18 | 0/17 | 0/16 | 1/16 |
| GastroenteritisInfections and infestations | 0/18 | 0/17 | 1/16 | 0/16 |
| PneumoniaInfections and infestations | 0/18 | 0/17 | 1/16 | 0/16 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/18 | 0/17 | 1/16 | 0/16 |
| Event | Placebo - Double Blind | Tadalafil - Double Blind | Placebo/Tadalafil - Open-Label Treatment | Tadalafil/Tadalafil - Open-Label Treatment |
|---|---|---|---|---|
| HeadacheNervous system disorders | 2/18 | 5/17 | 2/16 | 3/16 |
| VomitingGastrointestinal disorders | 0/18 | 0/17 | 0/16 | 3/16 |
| NasopharyngitisInfections and infestations | 0/18 | 0/17 | 1/16 | 3/16 |
| DizzinessNervous system disorders | 0/18 | 0/17 | 1/16 | 3/16 |
| InfluenzaInfections and infestations | 0/18 | 3/17 | 0/16 | 1/16 |
| Upper respiratory tract infectionInfections and infestations | 1/18 | 3/17 | 0/16 | 2/16 |
| Penis disorderReproductive system and breast disorders | 0/9 | 1/7 | 0/8 | 0/6 |
| Spontaneous penile erectionReproductive system and breast disorders | 0/9 | 1/7 | 1/8 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 0/18 | 0/17 | 2/16 | 0/16 |
| Abdominal pain upperGastrointestinal disorders | 0/18 | 0/17 | 0/16 | 2/16 |
All participants who received at least one dose of study drug. Per protocol and statistical analysis plan (SAP), the primary and secondary analysis were performed to compare all tadalafil participants together versus all placebo participants together.
| Age, Continuous(years) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Mean | 12.8 ± 3.39 | 14.1 ± 3.49 | 13.5 ± 3.45 |
| Sex: Female, Male(Participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Female | 9 | 10 | 19 |
| Male | 9 | 7 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 8 | 15 |
| Not Hispanic or Latino | 6 | 4 | 10 |
| Unknown or Not Reported | 5 | 5 | 10 |
| Race (NIH/OMB)(Participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 3 | 4 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 14 | 12 | 26 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Japan | 1 | 1 | 2 |
| Turkey | 2 | 1 | 3 |
| Brazil | 9 | 6 | 15 |
| Mexico | 1 | 4 | 5 |
| Israel | 2 | 4 | 6 |
| France | 1 | 1 | 2 |
| Germany | 1 | 0 | 1 |
| Poland | 1 | 0 | 1 |
| 6 Minute Walk Distance(Meters) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Mean | 476.7 ± 105.11 | 485.8 ± 160.231 | 481.1 ± 132.77 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Feb 2014 to primary completion in Mar 2019, 61 months.
Results were first posted in Mar 2020, 1 year after primary completion.
Of 31 phase 3 interventional studies under Hypertension, Pulmonary, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 83. This study's 61 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil